08.03.17
Colorescience has announced it has completed $15 Million in Series C Preferred Stock Financing.
The round was led by 1315 Capital, L.P., a Philadelphia-based healthcare investment firm that specializes in providing expansion and growth capital to specialty pharmaceutical, medical technology, and healthcare services companies.
Adele Oliva, founding partner at 1315 Capital, has joined the Colorescience Board of Directors.
Oliva comments, "We are thrilled to be working with the team at Colorescience to support the growth of their products given their focus on skin health and protection. Skin is the body's largest organ, and Colorescience products provide one of the highest quality solutions for medical professionals and consumers."
Colorescience CEO Mary Fisher adds, "This investment comes at an important inflection point in our growth at Colorescience and allows us to further invest in innovation and firmly establish our sales and marketing leadership in the aesthetics and beauty industry. We are particularly pleased to partner with 1315 Capital given their team's long and proven track record of backing successful high-growth healthcare companies."
Photo: Colorescience's Sunforgettable Brush-on Sunscreen SPF 50